

SCIENTIA MEETINGS

PROGRAM

VACCINES 2023

BRONZE SPONSOR



EXHIBITORS




VACCINES SUMMIT-2023

NOVEMBER 13-15, 2023
BOSTON, MA



SCIENTIA MEETINGS

Website: <https://scientiameetings.com/conferences/vaccines/> | Ph: 1-815-595-8049 | Email: venky@sciresgroup.net



About Organizer:

Scientia Meetings understand the importance of networking and collaboration. Conferences are not just about discussion, but about sharing knowledge and research work, new ideas, and a lot of opportunities. We are launching events in the country to create real networking with scientists and researchers from research institutes, companies, laboratories, and government agencies. We aim to have our events with only a moderate number of invited guests/delegates attending related to discipline and to create a platform for conversations leading to opportunities according to their individual needs. Our aim is to provide a platform for research scholars, scientific leaders, and decision-makers to come together and share their research findings with other scientific professionals which help to improve the sharing of knowledge and easy access to scientific information.

We provide a unique opportunity to share your innovative ideas, evaluate your research works, and promote collaborative work through networking sessions for a brighter future.

About Vaccines Summit-2023:

Scientia Meetings invites participants across the globe to attend its second edition of Vaccines Summit which is going to take place during November 13-15, 2023, and is organized around the theme “next-generation vaccines treatment and diagnostics that save lives”, Vaccines Summit-2023 is comprised of various sessions designed to offer comprehensive symposiums that address current issues in the field of vaccine research and provides a fantastic opportunity to network with your peers from academia and industry.

Corporate Partnering: Vaccines Summit-2023 help commercialize your innovations and build your business development pipeline through corporate partnering. We will arrange a one-on-one partnering meeting on request. We will share the conference attendees list with you, a month before the conference and arrange for one-on-one meetings with selected corporate representatives.

How does this conference help young scientists? Vaccines Summit-2023 not only opens doors to your career, but also opens your eyes to future opportunities, new cultures, and international perspectives. With the majority of the students interested in doing higher studies abroad, the students’ marketing forum provides an opportunity for Postgraduate and Undergraduate students to have formal communication with University representatives from around the world. Postgraduate student recruitment is increasingly becoming a strategic priority for higher education institutions. Vaccines Summit-2023 provides an excellent networking opportunity for potential collaboration with businesses and organizations for students.

Investment opportunities: Industry prospectors are looking for breakthrough technologies that are ready for licensing, corporate partnering, or investment opportunities. This can include prototypes, demonstrations, and display booths to showcase your innovative solutions at Vaccines Summit-2023. Pitch your idea to an industrial expert jury to raise the capital you need to get started.

Get *Whova* for Vaccines Summit 2023

Official Event App

- Explore the **professional profiles** of event speakers and attendees
- Send **in-app messages** and **exchange contact info**
- **Network and find attendees** with common affiliations, educations, shared networks, and social profiles
- Receive **update notifications** from organizers
- Access the **event agenda**, GPS guidance, maps, and parking directions at your fingertips



Download Whova and take your event mobile.



Get Whova from the App Store or Google Play.

Please sign up for the app with your **social media account** or **email**

The event invitation code is:

difgdpk8gp

You will be asked for an event invitation code after installing Whova



VACCINES SUMMIT - 2023

IMMUNOCOMPROMISED

**Next-Generation COVID-19
Vaccine, GEO-CM04S1
Demonstrates Potent
Antibody and Cellular
Immunity in
Immunocompromised
Patients**

PHASE 2

CLINICAL PROGRAM

GEO-CM04S1

NCT 04639466:

**as a booster
among healthy patients**

NCT 05672355:

**as a booster among
immunocompromised
patients**

NCT 04977024:

**as a primary
vaccine among
immunocompromised
patients**

JOIN US:

MUKESH KUMAR, PH.D.

**Associate Professor, Department of Biology,
Georgia State University**

MVA-vectored multi-antigen COVID-19 vaccines induce protective immunity against SARS-CoV-2 variants spanning Alpha to Omicron in preclinical animal models.

**LEARN MORE ABOUT GEOVAX'S
DEVELOPMENT AND PROGRESS**





Join our Talent Community

We're reimagining how medicines are created and delivered, and we're looking for people to join us on this incredible journey.



Sound interesting?

Scan the QR code to register for Moderna's Talent Community before speaking with a member of our team.

moderna

*You can change
everything*

CTL LABORATORIES

Contract Immune Monitoring Services

● Services

- Cryopreservation of your clinical trial PBMCs
- T cell, B cell immunoassays and AAV assays
- ELISPOT, ELISA, NAb, CBA, FACS, and more
- CLIA Certified, FDA GCP and GLP compliant
- Diverse Test systems- Human, mouse, NHP, etc.
- Preclinical and Clinical Phases I, II, III, and post licensure
Customized assay development, validation, and testing

● Standardization

- Cryopreserved Human PBMC
- ELISPOT kits
- Reagents; serum-free cryopreservation solutions
- Image Analyzers: ELISPOT, FluoroSpot, BioSpot,
Cell Counter, and other applications

- Chemistry
- Carrier proteins
- Conjugation Services



Please join FinaBio for *Happy Hour*
on November 14th
after the conjugate vaccine session is over

Carrier Proteins for Conjugate Vaccines

EcoCRM[®] (CRM₁₉₇), Tetanus toxin and Q β Virus-Like Particles

FINABIO CARRIER PROTEIN PORTFOLIO

TTHc Tetanus toxin fragment	EcoCRM [®] CRM ₁₉₇	8MTT Modified tetanus toxin	Q β VLP
50 kDa	58.4 kDa	150 kDa	28 nm- diameter nanoparticle
heavy chain fragment C	CRM ₁₉₇ , a widely used genetically detoxified diphtheria toxin	8MTT is the first genetically detoxified tetanus toxin	High stability
Preclinical	EcoCRM [®] has been extensively compared to CRM ₁₉₇ from other sources ¹	8 mutations to fully detoxify	Contains T cell epitopes
Extensive literature		50x10 ⁶ less toxic than tetanus toxin	High level of symmetry
Anti-TTHc neutralizes toxin	EcoCRM [®] available for research & clinical use	Large size allows for higher hapten: protein ratios	180 identical subunits

Changing the way you think about Biorepositories

Cryostorage priced competitively for virtually any need

- Facility has approximately 795,000 cubic feet of overall space for 1600 ultra low and cryogenic freezers

Long or mid-term inventory storage and management

- Cost-effective, space-saving solutions for storage of samples for retention period compliance.
- Inventory consolidation and equipment relocation programs available.

Any temperature-controlled environment you require

- Ambient
- Refrigerated (2–8° C)
- Frozen (–20/–30 and –80° C)
- Cryogenic (–196° C)

Logistical excellence with full control of transfers

- Enhancing your capability for inventory tracking, vial-level labeling, monitoring, retrieval, and disposal.
- Validated cloud-based temperature monitoring system and LIMs offers redundancy and API ability to interface with other systems to track sample storage and distribution.

Security and access that surpasses the industry's highest standards

- 24/7 cloud-based monitoring system.
- Advanced user portal enables printing of UID, tracking of individual identifier with custom fields and search features.
- GxP compliant and robust quality management system.
- Redundant power backup systems.
- FM 200 fire suppression system; Vault security system with 4-hour fire rating.
- Full video surveillance with facial recognition and search enabled video tracking.



OUR INTEGRATED SERVICES

BioMice Humanized Models

- Humanized Immune Checkpoint Mice
- Immunodeficient B-NDG Mice for Xenograft Studies
- Humanized Cytokine & GPCR Mice
- Humanized Tumor Cell Lines

Antibody & ADC Discovery

- Fully Human Therapeutic Antibodies, Surrogates, Anti-idiotypic & Bispecific/Multispecific Antibodies
- GPCR & TCRm Discovery Platforms
- Single B Cell Cloning Technology
- Best-In-Class Fully Human Antibody Mouse

Pharmacology Services

- Expertise in Efficacy Evaluation of Novel Therapeutics
- In Vitro Studies, In Vivo Assays, PK, PD, Toxicity Assessments
- Syngeneic Models, Xenograft Tumor Models, Inflammatory Disease Models

Gene Editing Services

- CRISPR/Cas9-Based Extreme Genome Editing (EGE™)
- ESC-Based Homologous Recombination (Large Fragments)
- Custom Models or Cell Lines


BIOCYTOGEN


INNOVATIVE SOLUTIONS TO ACCELERATE DRUG DISCOVERY



INDUSTRY LEADING **VACCINE CDMO** FOR GLOBAL VACCINE DEVELOPMENT AND MANUFACTURING

Enabling Partnerships to Benefit Global Health Initiatives

WuXi Vaccines, a subsidiary of WuXi Biologics, brings a level of expertise, experience and state-of-the-art facilities to enable your project to be conducted right the first time. With over 48 projects in development and multiple commercial vaccines manufactured at globally GMP-certified facilities, we provide world-class integrated development and manufacturing platforms to expedite your vaccine to the clinic and the market.



wuxivaccines.com


WuXi Vaccines





The Antibody Profiling Company

Antibody Repertoire: The Next Level of Biomarker Information

~800 trillion antibodies in every drop of blood

Performed Proteomics?

With Antibody Repertoire Profiling, we can characterize the Antigen Reactivities of Individuals



Introducing SERA

A discovery service offering a universal serology platform that utilizes bacterial display peptide library technology and next generation sequencing to broadly profile antibody repertoires and identify the antigens and epitopes associated with many diseases - all in a single assay.

Benefits

- ✓ Unlimited **multiplexing of serology tests** from a single assay.
- ✓ **High-resolution epitope mapping** in infectious diseases, cancer and autoimmune disease
- ✓ **Simultaneous profiling of multiple pathogens**
- ✓ **Ideal for Antigen Identification-**
 - Diagnostic and therapeutic applications
 - Disease-subtype identification
- ✓ **Scientific Support** – Leading experts in epitope analysis and bioinformatics
- ✓ **Clinically Relevant Analysis - State-of-the-Art Database** - with 26,000+ profiled antibody repertoires from individuals with infections, autoimmune diseases, cancers as well as healthy blood donors
- ✓ **Longitudinal Studies** – Ability to visualize disease exposures as they occur or recur

Drug Discovery

Research Applications

Immuno-
Therapeutics



Target
Discovery



Vaccines



Immunodominant
Epitopes



Biomarkers of
Response



serimmune.com



info@serimmune.com

Day-1**Monday - November 13, 2023****KEYNOTE PRESENTATIONS****Grand Ballroom**

08:00-18:20 EST (Eastern Time Zone)


Session Chair: David Weiner

Executive Vice President, The Wistar Institute, Director, Vaccine & Immunotherapy Center

08:00-08:30
Pre-Recorded
Presentation**Prospects for vaccination against human cytomegalovirus****Stanley A. Plotkin**

Consultant and Emeritus Professor of the University of Pennsylvania, Vaxconsult, LLP

08:30-09:00

**Development of a COVID-19 vaccine****Sir Andrew J. Pollard**

Ashall Professor of Paediatric Infection and Immunity and Director of Oxford Vaccine Group

09:00-09:30

**Correlates of protection for COVID-19 vaccines****Dan Barouch**

Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center

09:30-10:00

**Precision Vaccines: Bringing Precision Medicine to Vaccinology****Ofer Levy**

Staff Physician & Principal Investigator, Director, Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital Professor, Harvard Medical School

10:00-10:20 **Coffee Break**

10:20-10:50

**Monitoring COVID-19 vaccine safety during the pandemic: successes, opportunities, and outstanding challenges****Walter Straus**

Vice-President, Clinical Safety, Moderna

10:50-11:20

**Nanoparticle intranasal vaccine prevents forward airborne transmission to naïve recipient hamsters****Jay A. Berzofsky**

National Cancer Institute, NIH

11:20-11:50

**Use of VSV vaccine platform for epidemic preparedness and response; update from current studies and innovative partnership strategies****Swati Gupta**

VP, Emerging Infectious Diseases and Epidemiology, IAVI

11:50-12:20

**NIAID, vaccine research center's pandemic preparedness and emergency response: Looking at the past to shape our future****Karin Bok**

Acting Deputy Director, Director of Pandemic Preparedness and Emergency Response, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health



12:20-12:50



Translating the COVID-19 learnings into long-lasting innovation: how new technologies could help address global health issues and improve pandemic preparedness

Ruben Rizzi

Vice President of Global Regulatory Affairs, BioNTech

12:50-14:00 **Lunch Break**

14:00-14:30



Ad26 viral vector based vaccines for COVID-19 and HIV-1

Hanneke Schuitemaker

VP, Head of Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines and Prevention B.V

14:30-15:00



Data-science-supported formulation development creates value for vaccine products

Sabine Hauck

Leukocare

15:00-15:30



Next generation mRNA Design-Increasing mRNA Potency with a New Cap Analog

Kate Broderick

Chief Innovation Officer, Maravai LifeSciences

15:30-16:00



Durable immunity, lessons from measles and mumps

Richard B. Kennedy

Professor of Medicine, Co-Director, Mayo Clinic Vaccine Research Group

16:00-16:20 **Coffee Break**

16:20-16:50



Nucleic acid tools for driving vaccine immunity and gene delivery for improved immune impact

David Weiner

Executive Vice President, Director, Vaccine & Immunotherapy Center, The Wistar Institute

16:50-17:20



UVC: Universal Vaccine Cell

Tom Henley

Chief Scientific Officer, Intima Bioscience

17:20-17:50



A strategic model and industry collaboration for sustainable development of vaccines against neglected diseases

Francesco Berlanda Scorza

VP, Global Health R&D Vaccines Head and GVGH Institute Director, GSK Vaccines Institute for Global Health

17:50-18:20





Accelerating recombinant protein vaccine development and manufacturing for disease X

Jian He (Jason)

CMC Head, WuXi Vaccines

18:20-19:30 **RECEPTION @ Grand Ballroom Foyer**

18:20-19:30 **POSTER PRESENTATIONS**

- P-01**  **Neutralization of contemporary omicron subvariants after bivalent booster and XBB.1.5 breakthrough infections**
Ping Ren
University of Texas Medical Branch
- P-02**  **Neoantigen adenoviral cancer vaccine generates improved CD8+ T-cell responses compared to conventional peptide vaccine**
Gabriel Dagotto
Harvard University
- P-03**  **Advanced imaging techniques for pre-clinical differentiation of enabled vaccine formulations**
Michael McNevin
Merck and Co., Inc
- P-04**  **Concurrent administration of COVID-19 and influenza vaccines enhances spike-specific antibody responses**
Susanna Barouch
Ragon Institute of MGH, MIT, and Harvard
- P-05**  **A systems serology- and structural biology-based approach to identify humoral correlates of viral clearance**
Ryan P McNamara
Ragon Institute of MGH, MIT, and Harvard
- P-06**  **Development of an anti-ang2 vaccine and characterization of its effects on AVMs in BMP9/10-deficient mice**
Sima Qutaina
Feinstein Institutes for Medical Research
- P-07**  **C1 gene expression platform: Rapid, high yield, and lower cost way to develop and manufacture biologics**
Mark Emaflarb
Dyadic International Inc
- P-08**  **Development of a novel *Shigella* quadrivalent conjugate vaccine using O-polysaccharide and IpaB carrier protein**
Shagndong Guo
Inventprise Inc
- P-09**  **Compartmentalized vaccine responses in the intestine during murine norovirus infection**
Sanghyun Lee
Brown University

Day-2

Tuesday - November 14, 2023

CONJUGATE VACCINE

Cabot Ballroom

08:00-15:00 EST (Eastern Time Zone)

Session Chair: **Andrew Lees**
Fina Biosolutions

08:00-08:30



Conjugation chemistry, carrier proteins and antigens: promoting conjugate vaccine development

Andrew Lees
Fina Biosolutions

08:30-09:00



Glycoconjugate vaccines to prevent AMR pathogens

Roberto Adamo
GSK

09:00-09:30



GA-VAX - Development of a conjugate vaccine targeting a genetic form of Amyotrophic Lateral Sclerosis (C9orf72)

Robert van der Put
Intravacc.nl

09:30-10:00



Preparation of bacterial polysaccharide-protein conjugate vaccines

Wei Zou
National Research Council of Canada

10:00-10:20 Coffee Break

10:20-10:50



Conjugate vaccines for substance abuse adjuvanted with army liposome formulation and aluminum hydroxide

Gary R. Matyas
US Military HIV Research Program, Walter Reed Army Institute of Research

10:50-11:20



Recent advancements in the glycoconjugate vaccines field

Francesco Berti
GSK Vaccines


11:20-11:50



Conjugation increases the immunogenicity and efficacy of T-cell inducing Glycolipid-Peptide (GLP) vaccines

Gavin Painter
Victoria University Wellington

11:50-12:20



Peptide-glycolipid conjugate vaccines targeting Hepatitis B virus antigens

Olivia Burn
Malaghan Institute of Medical Research



12:20-12:50



WISIT vaccines: Next generation vaccine platform leveraging skin immunity to treat chronic diseases

Markus Mandler
Tridem Bioscience

12:50-14:00 **Lunch Break**

14:00-14:30



Development of a pneumococcal conjugate vaccine and novel vaccines through research driven efforts in India

Ramesh Matur
Biological E Ltd

14:30-15:00



Rational design of next-generation glycoconjugate vaccines inducing highly functional antibodies

Giuseppe Stefanetti
Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo

Happy hours co-sponsored by



Day-2

Tuesday - November 14, 2023

CORONAVIRUS (COVID-19)

Grand Ballroom

08:00-12:40 EST (Eastern Time Zone)

Session Chair: **Shahin Gharakhanian**
Decoy Therapeutics

08:00-08:20



MVA-vectored multi-antigen Covid-19 vaccines induce protective immunity against SARS-CoV-2 variants spanning Alpha to Omicron in preclinical animal models

Mukesh Kumar
Georgia State University

08:20-08:40



Superior mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant

Michael Schotsaert
Icahn School of Medicine at Mount Sinai

08:40-09:00



Modular nanoarray vaccine for SARS-CoV-2

Yuri Lyubchenko
University of Nebraska Medical Center

09:00-09:20



How to develop a long-lasting COVID-19 vaccine

Gongyi Zhang
National Jewish Health



09:20-09:40



Comparative efficacy of antiviral strategies targeting different stages of the viral life cycle

Barbara Jones
IBM Quantum

09:40-10:00



Intranasal Ad5 Omicron vaccine can build effective mucosal immunity wall against broad spectrum of SARS-CoV-2 variants

Ling Chen
Guangzhou Laboratory, Guangzhou Medical University

10:00-10:20 **Coffee Break**

10:20-10:40



Prevention of Covid-19 beyond the vaccine needle: Targeting transmission via development of a novel antiviral fusion peptide-based prophylactic nasal spray

Shahin Gharakhanian
Decoy Therapeutics

10:40-11:00



Durable immunity to SARS-CoV-2 infection and vaccination

Mehul Suthar
Emory University School of Medicine

11:00-11:20



Development of next generation vaccines against SARS-CoV-2 infection

Tian Wang
University of Texas Medical Branch

11:20-11:40



Minimalistic pan-coronavirus vaccines with a safer LNP delivery system and devoid of adverse spike epitopes

Janet K. Yamamoto
University of Florida

11:40-12:00



Selection for immune evasion in SARS-CoV-2 revealed by high-resolution epitope mapping and sequence analysis

Jorg Hermann Fritz
McGill University

12:00-12:20



Design of a subunit precision vaccine against SARS-CoV-2

M. Dahmani Fathallah
Arabian Gulf university

12:20-12:40



UB-612: A novel peptide/protein subunit COVID-19 vaccine booster stimulated broadly neutralizing and Fc-mediated effector antibodies in a head-to-head Phase 3 randomized clinical trial

Alexander Rummyantsev
Vaxxinity

12:40-13:40 **Lunch Break**

NEW VACCINE DEVELOPMENT

Grand Ballroom

13:40-18:40 EST (Eastern Time Zone)

 Session Chair: **John Shon**
Serimmune

13:40-14:00


Vaccines and monoclonal antibodies for treatment and prevention of opioid use disorders and opioid-related overdoses
Marco Pravetoni

University of Washington School of Medicine

14:00-14:20


Robust immunogenicity and protection with PlaCCine: A novel DNA vaccine delivered with a functionalized polymeric delivery system
Jean D Boyer

Imunon

14:20-14:40


Safety profile and analytical assessment of a cross-platform trivalent combination vaccine against invasive nontyphoidal salmonellosis and typhoid fever
Francesco Citiulo

GSK Vaccines Institute for Global Health

14:40-15:00


Development of a broadly cross-reactive vaccine against rhinoviruses
Sebastian L. Johnston

Imperial College London

15:00-15:20


Interrogation of human monoclonal antibodies induced by meningococcus B vaccination to identify cross-protective antigens against gonococcus
Oretta Finco

GSK (Bacterial Vaccines Unit)

15:20-15:40


SERA- universal serology enabling high-throughput, antigen agnostic studies of adaptive immune responses
John Shon

Serimmune


15:40-16:00 Coffee Break

16:00-16:20


The respiratory syncytial virus G protein enhances the immune responses to the RSV F protein in an enveloped virus-like particle vaccine candidate
Trudy Morrison

University of Massachusetts Chan Medical School

16:20-16:40


Correlative outcomes of maternal immunization against RSV in cotton rats
Jorge C. Blanco

Sigmovir Biosystems Inc.

16:40-17:00



CD40 ligand (CD40L)-based, dendritic cell-targeted vaccine ("FortiVac") as a platform technology for high-level CD8+ T cell responses

Richard Kornbluth

Multimeric Biotherapeutics, Inc.

17:00-17:20



Development of a pan-species/pan-disease T cell vaccine platform to address one health zoonotic risks

Thomas Tillett

MBF Therapeutics

17:20-17:40




mRNA vaccines against Lassa virus

Alexander Bukreyev

University of Texas Medical Branch

17:40-18:00



Nanoparticle-based antigen favors high level of humoral immune responses and increases antigenicity of highly glycosylated protein

Yi Yang

Hunan Agricultural University

18:00-18:20




Development of a Marburgvirus subunit vaccine adjuvanted with a novel TLR7/TLR8 Agonist

Shweta Kailasan

Abvacc

18:20-18:40



ultralPVTM: An improved polio vaccine

Stephen J. Dollery

Biological Mimetics, Inc

Day-3

Wednesday - November 15, 2023

ORAL PRESENTATIONS

Grand Ballroom

08:00-18:00 EST (Eastern Time Zone)

Infectious & Non-Infectious Diseases

Session Chair: **Robert O. Dillman**

AIVITA Biomedical, Inc

08:00-08:20



SchistoShield®, Sm-p80-based schistosomiasis vaccine: Human clinical trials in USA and Africa

Afzal A. Siddiqui

Texas Tech University Health Sciences Center

08:20-08:40



Development of an effective nontoxigenic *Clostridioides difficile*-based oral vaccine against *C. difficile* infection

Xingmin Sun

University of South Florida



08:40-09:00



Ex vivo antigen-loading of dendritic cells as a platform for personal cancer and infectious disease vaccines

Robert O. Dillman
AIVITA Biomedical, Inc

09:00-09:20



An ecosystem for the rapid generation of biological reagents against infectious diseases

Sumana Sundarmurthy
Sino Biological

09:20-09:40



DNA-based delivery of antiviral antibodies for infectious disease prevention

Rachel A. Liberatore
RenBio

09:40-10:00



Immune monitoring read outs when vector-based vaccines are used: including ELISPOT assays

Magdalena Tary-Lehmann
Cellular Technology Limited

10:00-10:20



The underlying genetic architecture of the immune system responsible for immunodominance

Stephen J Elledge
Harvard Medical School

10:20-10:40



How advances in artificial intelligence are optimizing the deployment and utilization of life-saving infectious disease countermeasures to high-consequence epidemics

Kamran Khan
BlueDot

10:40-11:00 Coffee Break

Cancer Vaccines & Immunotherapy

Session Chair: **Farshad Guirakhoo**, ExpreS2ion Biotechnology

11:00-11:20



Preclinical proof of concept studies of a novel human HER-2 virus like particle as a vaccine candidate for human breast cancers

Farshad Guirakhoo
ExpreS2ion Biotechnology

11:20-11:40



Exploring T-Cell pathways to enhance immunotherapies in cancer and infection

Christopher E. Rudd
Universite de Montreal

11:40-12:00



Stimulation of anti-tumor responses with small molecules that induce Z-DNA

Alan Herbert
InsideOutBio, Inc

12:00-12:20



Development of an enhanced IL-12-containing in situ vaccine for the treatment of solid tumor patients, refractory to anti-PD(L1) agents

Robert Hamilton Pierce

Attivare Therapeutics

12:20-13:20 Lunch Break

Influenza Vaccines

13:20-13:40



Approaches to enhance the generation of broadly reactive influenza-specific antibodies in newborns

Martha Alexander-Miller

Wake Forest University School of Medicine

13:40-14:00



Rapid development and flexible scale of complex recombinant proteins and antigens including ferritin nanoparticles for infectious diseases including COVID-19 and seasonal and pandemic influenza

Mark Emaflarb

Dyadic International Inc

14:00-14:20



Liposome-display of antigens: A powerful approach for vaccine development

Jonathan Lovell

University at Buffalo

Vaccine adjuvants

14:20-14:40



Immunomodulators identified via high-throughput screening enhance control of vaccine adjuvanticity

Matthew Rosenberger

University of Chicago

14:40-15:00



Adjuvantation with mRNA encoding IL-12 overcomes mRNA vaccine limitations

Byron Brook

Boston Children's Hospital

15:00-15:20



Harnessing sustained release technologies to produce robust, durable, and high-quality immunity

Eric Andrew Appel

Stanford University

15:20-15:40




mRNA vaccine against malaria tailored for liver-resident memory T cells

Gavin Painter

Victoria University Wellington

15:40-16:00

**Development of saponin-based adjuvant IA-05 for subunit-vaccines****Pi-Hui Liang**

Professor, School of Pharmacy, National Taiwan University, Founder and CEO of ImmunAdd, Inc. Taipei, Taiwan

16:00-16:20 Coffee Break

HIV VaccineSession Chair: **Siddappa N. Byraredddy**

University of Nebraska Medical Center

16:20-16:40

**Induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques with protein and mRNA vaccination****Kevin O. Saunders**

Duke Human Vaccine Institute

16:40-17:00

**HIV clade C vaccine adjuvanted with NE/AS01B in SHIV-challenged macaques****Siddappa N. Byraredddy**

University of Nebraska Medical Center

17:00-17:20

**Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1****Catarina Hioe**

Icahn School of Medicine at Mount Sinai

17:20-17:40

**Antiviral vaccine route and form potentially impact immunogenicity and efficacy****Mark Connors**

NIAID/LIR

17:40-18:00


**Synergy between tissue resident memory CD8 T cells and antibody for protection against HIV****Rama Rao Amara**

Emory National Primate Research Center



SCIENTIA MEETINGS

VACCINES SUMMIT-2024<https://scientiameetings.com/conferences/vaccines/>**VACCINES SUMMIT-2023**
November 13-15, 2023 | Boston, MA



SCIENTIA MEETINGS

PROGRAM

VACCINES 2023

BRONZE SPONSOR



EXHIBITORS



VACCINES SUMMIT-2023

NOVEMBER 13-15, 2023
BOSTON, MA



SCIENTIA MEETINGS

Website: <https://scientiameetings.com/conferences/vaccines/> | Ph: 1-815-595-8049 | Email: venky@sciresgroup.net